Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.1080/10428194.2016.1201573.

Funding

This study has been completed by the following Cooperative Group Networks: SWOG, CALGB/Alliance, ECOG, and the AIDS Malignancy Consortium.

This investigation was supported in part by the following PHS/DHHS grant numbers awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI), National Clinical Trials Network (NCTN): CA180888, CA180819, CA180821, CA180820, CA180799, CA180816, CA180801; CA180835; CA180858, CA180801, CA180846, CA180835, CA180818, CA180828, CA180826, CA180834; by the NIH/NCI Community Oncology Research Program (NCORP): CA189830, CA189971, CA189808, CA189854, CA189821, CA189848, CA189858, CA189860, CA189872, CA189856; by NIH/NCI legacy grants CA31946, CA 46368, CA35119, CA13612, CA46282, CA68183, CA37981, CA12644, CA76448, CA46136, CA58416; by the NCI AIDS Malignancy Clinical Trials Consortium (AMC): CA121947 and by the NIH American Recovery and Reinvestment Act of 2009 (ARRA) grant 3U10CA032102-30S1. AVD is supported by the Lymphoma Research Foundation Clinical Investigator Career Development Award.